Use este identificador para citar ou linkar para este item:
https://www.arca.fiocruz.br/handle/icict/20526
ASSESSMENT OF MLL METHYLTRANSFERASE GENE EXPRESSION IN LARYNX CARCINOMA
Autor(es)
Afiliação
University of Brasília. Faculty of Health Sciences. Laboratory of Molecular Pathology of Cancer. Brasília, DF, Brasil / University of Centro Oeste. Department of Pharmacy. Guarapuava, PR, Brasil
University of Brasília. Faculty of Health Sciences. Laboratory of Molecular Pathology of Cancer. Brasília, DF, Brasil
University of São Paulo. Medical School of Ribeirão Preto. Center for Cell Therapy and Regional Blood Center. Ribeirão Preto, SP, Brazil
University of São Paulo. Medical School of Ribeirão Preto. Department of Internal Medicine. Ribeirão Preto, SP, Brazil
University of São Paulo. Medical School of Ribeirão Preto. Department of Internal Medicine. Ribeirão Preto, SP, Brazil
University of São Paulo. Medical School of Ribeirão Preto. Center for Cell Therapy and Regional Blood Center. Ribeirão Preto, SP, Brazil / University of São Paulo. Medical School of Ribeirão Preto. Department of Internal Medicine. Ribeirão Preto, SP, Brazil
University of São Paulo. Medical School of Ribeirão Preto. Department of Internal Medicine. Ribeirão Preto, SP, Brazil
University of Brasília. Faculty of Health Sciences. Laboratory of Molecular Pathology of Cancer. Brasília, DF, Brasil / University of Centro Oeste. Department of Pharmacy. Guarapuava, PR, Brasil
University of Brasília. Faculty of Health Sciences. Laboratory of Molecular Pathology of Cancer. Brasília, DF, Brasil / University of Centro Oeste. Department of Pharmacy. Guarapuava, PR, Brasil
University of Brasília. Faculty of Health Sciences. Laboratory of Molecular Pathology of Cancer. Brasília, DF, Brasil
University of São Paulo. Medical School of Ribeirão Preto. Center for Cell Therapy and Regional Blood Center. Ribeirão Preto, SP, Brazil
University of São Paulo. Medical School of Ribeirão Preto. Department of Internal Medicine. Ribeirão Preto, SP, Brazil
University of São Paulo. Medical School of Ribeirão Preto. Department of Internal Medicine. Ribeirão Preto, SP, Brazil
University of São Paulo. Medical School of Ribeirão Preto. Center for Cell Therapy and Regional Blood Center. Ribeirão Preto, SP, Brazil / University of São Paulo. Medical School of Ribeirão Preto. Department of Internal Medicine. Ribeirão Preto, SP, Brazil
University of São Paulo. Medical School of Ribeirão Preto. Department of Internal Medicine. Ribeirão Preto, SP, Brazil
University of Brasília. Faculty of Health Sciences. Laboratory of Molecular Pathology of Cancer. Brasília, DF, Brasil / University of Centro Oeste. Department of Pharmacy. Guarapuava, PR, Brasil
University of Brasília. Faculty of Health Sciences. Laboratory of Molecular Pathology of Cancer. Brasília, DF, Brasil / University of Centro Oeste. Department of Pharmacy. Guarapuava, PR, Brasil
Resumo em Inglês
Larynx cancer is the second most common type of cancer among all head and neck cancers. Deregulation of epigenetic effectors, including altered expression of histone methyltransferases from the MLL (mixed lineage leukemia) family, have been reported in many cancer types, yet little is known concerning their involvement in larynx cancer. Our objective was to determine the expression profile of MLL genes in larynx carcinoma and normal adjacent tissues and correlate this profile to tumor characteristics. We analyzed the expression profile of 5 MLL genes in 13 cases of larynx carcinoma and their adjacent non-tumor tissues using quantitative real-time PCR. MLL3 was significantly downregulated in tumor samples compared to their normal counterparts, and all MLL genes showed decreased expression in advanced tumors compared to tumors in the initial stage. Altered expression in a single MLL gene was associated with a similar alteration in the other MLL genes, revealing a strong correlation of expression in each individual patient. In conclusion, MLL genes may have similar transcriptional control, and decreased expression of these genes may contribute to larynx cancer progression.
Compartilhar